Rabeprazole sodium enteric-coated tablets generally have no effect on the kidneys and are mainly metabolized by the liver. Rabeprazole sodium enteric coated tablets belongs to proton pump inhibitors, after oral intake is absorbed in the intestinal tract, it can inhibit gastric acid secretion, mainly used in the treatment of gastritis, gastric ulcers, duodenal ulcers, reflux esophagitis, Droei-Ahl syndrome and other diseases. Serious adverse reactions include shock, pancytopenia, and hepatic dysfunction. The drug is metabolized primarily by the liver and usually has no effect on the kidneys as it is rarely metabolized by the kidneys. The drug should be taken under the supervision of a clinician. It is contraindicated for people who are allergic to the components of the drug.